Similarly, SLC22A17 overexpression plays a critical role in the pathogenesis of gastric and non-small cell lung cancer, representing a negative prognostic biomarker for such tumors [30, 61, 62]. Here, SLC22A17 is linked to non-small cell lung carcinoma.